Highlights of This Issue 5259

SPECIAL FEATURES

CCR Translations

5261 Intratumoral Anti-CTLA-4 Therapy: Enhancing Efficacy While Avoiding Toxicity
Aurélie Marabelle, Holbrook Kohrt, and Ronald Levy
See related article, p 5381

CCR New Strategies

5264 New Strategies in Endometrial Cancer: Targeting the PI3K/mTOR Pathway—The Devil Is in the Details
Andrea P. Myers

Molecular Pathways

5275 Molecular Pathways: MERTK Signaling in Cancer
Christopher T. Cummings, Deborah DeRyckere, H. Shelton Earp, and Douglas K. Graham

5279 Novel Clinically Relevant Genes in Gastrointestinal Stromal Tumors Identified by Exome Sequencing
Sebastian F. Schoppmann, Ursula Vinatzer, Niko Poptitsch, Martina Mittlböck, Sandra Liebmann-Reindl, Gerd Jomrich, Berthold Streubel, and Peter Birner

5282 A Sea Change in Melanoma
Susan E. Bates

5283 The Intersection of Immune-Directed and Molecularly Targeted Therapy in Advanced Melanoma: Where We Have Been, Are, and Will Be
Ryan J. Sullivan, Patricia M. LoRusso, and Keith T. Flaherty

5289 Adoptive T-cell Transfer Therapy and Oncogene-Targeted Therapy for Melanoma: The Search for Synergy
Mei Li M. Kwong, Bart Neyns, and James C. Yang

5293 CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
Patrick A. Ott, F. Stephen Hodi, and Caroline Robert

5299 Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma
Lawrence N. Kwong and Michael A. Davies

HUMAN CANCER BIOLOGY

5310 The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma
Karen E. Sheppard and Grant A. McArthur

5320 Characterization of CD145+/CD31+/CD105+ Circulating Cells in the Peripheral Blood of Patients with Gynecologic Malignancies

5325 Merkel Polyomavirus-Specific T Cells Fluctuate with Merkel Cell Carcinoma Burden and Express Therapeutically Targetable PD-1 and Tim-3 Exhaustion Markers
Olga K. Afanasiev, Lola Yelistratova, Natalie Miller, Kotaro Nagase, Kelly Paulson, Jayasri G. Iyer, Dafina Ibrani, David M. Koelle, and Paul Nghiem

5330 The Cell-Cycle Regulator CDK6: An Emerging Therapeutic Target in Melanoma
Karen E. Sheppard and Grant A. McArthur

5335 Characterization and Clinical Relevance of ALDHbright Populations in Prostate Cancer
Clémence Le Magnen, Lukas Bubendorf, Cyrill A. Rentsch, Chantal Mengus, Joel Gipponer, Tobias Zellweger, Malte Rieken, George N. Thalmann, Marco G. Cecchini, Markus Germann, Alexander Bachmann, Stephen Wyler, Michael Heberer, and Giulio C. Spagnoli

5345 Prognostic Significance of AMPK Activation and Therapeutic Effects of Metformin in Hepatocellular Carcinoma
Longyi Zheng, Wen Yang, Fuquan Wu, Chao Wang, Lexing Yu, Liang Tang, Bijun Qiu, Yuqiong Li, Linna Guo, Mengchao Wu, Gensheng Feng, Dajin Zou, and Hongyang Wang
**CANCER THERAPY: PRECLINICAL**

5381

**Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell-Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects**

Marieke F. Fransen, Tetje C. van der Sluis, Ferry Ossendorp, Ramon Arens, and Cornelis J.M. Melief

*See related article, p 5261*

5390

**Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2**

Brent N. Rexer, Ritwik Ghosh, Archana Narasanna, Mónica Valeria Estrada, Anindita Chakrabarty, Youngchul Song, Jeffrey A. Engelman, and Carlos L. Arteaga

5402

**The Integrin Inhibitor Cilengitide Affects Meningioma Cell Motility and Invasion**

Annette Wilisch-Neumann, Nadine Kliese, Doreen Pachow, Thomas Schneider, Jan-Peter Warnke, Werner EK Braunsdorf, Frank-Dietmar Böhner, Peter Hass, Diana Pasemann, Cornelia Helbing, Elmar Kirches, and Christian Mawrin

5413

**PIK3CA and AKT1 Mutations Have Distinct Effects on Sensitivity to Targeted Pathway Inhibitors in an Isogenic Luminal Breast Cancer Model System**

Julia A. Beaver, John P. Gustin, Kyung H. Yi, Anindita Chakrabarty, Matthew Thomas, Samuel F. Gilbert, D. Marc Rosen, Ben Ho Park, and Josh Lauring

**IMAGING, DIAGNOSIS, PROGNOSIS**

5423

**MicroRNA-31 Predicts the Presence of Lymph Node Metastases and Survival in Patients with Lung Adenocarcinoma**

Wei Meng, Zhengqin Ye, Ri Cui, James Perry, Vaia Dedoussis-Huebner, Alexander Huebner, Yao Wang, Bin Li, Stefano Volini, Hiroshi Nakanishi, Taewan Kim, Sung-Suk Suh, Leona W. Ayers, Patrick Ross, Carlo M. Croce, Arnab Chakravarti, Victor X. Jin, and Tim Lautenschlaeger

5434

**In Vivo Imaging of Prostate Cancer Using [186Ga]-Labeled Bombesin Analog BAY86-7548**


5444

**Unique DNA Methylation Loci Distinguish Anatomic Site and HPV Status in Head and Neck Squamous Cell Carcinoma**

Roberto A. Lleras, Richard V. Smith, Leslie R. Adrien, Nicolas F. Schlecht, Robert D. Burk, Thomas M. Harris, Geoffrey Childs, Michael B. Prystowsky, and Thomas J. Belbin

5456

**Prognostic Factors in Patients with Advanced Cancer: A Comparison of Clinicopathological Factors and the Development of an Inflammation-Based Prognostic System**

Barry J. Laird, Stein Kaasa, Donald C. McMillan, Marie T. Fallon, Marianne J. Hjermstad, Peter Fayers, and Pal Klepstad

5465

**HLA and Killer Immunoglobulin-like Receptor Genes as Outcome Predictors of Hepatitis C Virus–Related Hepatocellular Carcinoma**

Elisabetta Cariani, Massimo Pilli, Alessandro Zerbini, Cristina Rota, Andrea Olivani, Paola Zanelli, Adele Zanetti, Tommaso Trenti, Carlo Ferrari, and Gabriele Missale

**CANCER THERAPY: CLINICAL**

5474

**Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial**

Ana M. Gonzalez-Angulo, Funda Meric-Bernstam, Sant Chawla, Gerald Falchook, David Hong, Argun Akcakanat, Huiqin Chen, Aung Naing, Siqing Fu, Jennifer Wheler, Stacy Moulder, Thorunn Helgason, Shaoyi Li, Ileana Elias, Neil Desai, and Razelle Kurzrock
Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study

First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors

Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—Letter

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—Response

MGMT-STM27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951

A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non–Small Cell Lung Cancer

Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes

Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes

LETTERS TO THE EDITOR

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—Letter

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—Response

AC icon indicates Author Choice

CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org

For more information please visit www.aacrjournals.org
ABOUT THE COVER

Metformin administration significantly inhibited the growth of SMMC7721 cell-derived tumor xenografts in nude mice. The cover shows hematoxylin and eosin staining of the tumor tissue from control mice. For details, see the article by Zheng and colleagues on page 5372 of this issue.